Aclaris Therapeutics (FRA:8AT) Preferred Dividends : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Aclaris Therapeutics's preferred dividends for the three months ended in Dec. 2024 was €0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Aclaris Therapeutics Preferred Dividends Historical Data

The historical data trend for Aclaris Therapeutics's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Preferred Dividends Chart

Aclaris Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Preferred Dividends

Get a 7-Day Free Trial

Aclaris Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Aclaris Therapeutics Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Aclaris Therapeutics (FRA:8AT) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Aclaris Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

ACRS:USA 0H8T:UK

Address

701 Lee Road, Suite 103, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics Headlines

No Headlines